Search results

Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Last updated

23 November 2016

Evidence-based recommendations on nivolumab (Opdivo) for previously treated advanced renal cell carcinoma in adults

Type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on dapagliflozin (Forxiga) given with 2 other drugs for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Type

Technology appraisal guidance

Published

23 November 2016

Evidence-based recommendations on elbasvir–grazoprevir (Zepatier) for treating genotype 1 or 4 chronic hepatitis C (HCV) in adults

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on cobimetinib (Cotellic) with vemurafenib (Zelboraf) for unresectable or metastatic melanoma in adults with a BRAF V600

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor

Type

Technology appraisal guidance

Published

26 October 2016

Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on radium-223 dichloride (Xofigo) for treating hormone-relapsed prostate cancer with bone metastases

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia

Type

Technology appraisal guidance

Published

28 September 2016

Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy

Type

Technology appraisal guidance

Published

28 September 2016

This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.

Type

NICE guideline

Published

20 September 2016

Evidence-based recommendations on bosutinib (Bosulif) for previously treated chronic myeloid leukaemia in adults

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults

Type

Technology appraisal guidance

Published

24 August 2016

Evidence-based recommendations on cabazitaxel (Jevtana) for prostate cancer that has come back after it was treated with docetaxel

Type

Technology appraisal guidance

Last updated

24 August 2016

Evidence-based recommendations on nivolumab (Opdivo) with ipilimumab (Yervoy) for treating advanced (unresectable or metastatic) melanoma in adults

Type

Technology appraisal guidance

Published

27 July 2016

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del

Type

Technology appraisal guidance

Published

27 July 2016

Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia (AML) with more than 30% bone marrow blasts

Type

Technology appraisal guidance

Published

27 July 2016

Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults

Type

Technology appraisal guidance

Last updated

27 July 2016

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults who have had previous treatment with a

Type

Technology appraisal guidance

Last updated

27 July 2016

This guideline covers oral health, including dental health and daily mouth care, for adults in care homes. The aim is to maintain and improve their oral health and ensure timely access to dental treatment.

Type

NICE guideline

Published

05 July 2016

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on evolocumab (Repatha) for treating primary hypercholesterolaemia (high cholesterol) and mixed dyslipidaemia

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on belimumab (Benlysta) as an add-on treatment for active autoantibody-positive systemic lupus erythematosus

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on ceritinib (Zykadia) for advanced anaplastic lymphoma kinase positive non-small-cell lung cancer...

Type

Technology appraisal guidance

Published

22 June 2016

Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) for treating type 2 diabetes in adults

Type

Technology appraisal guidance

Published

25 May 2016

Evidence-based recommendations on topotecan, pegylated liposomal doxorubicin hydrochloride (Caelyx; PLDH), paclitaxel, trabectedin (Yondelis) and gemcitabine

Type

Technology appraisal guidance

Published

27 April 2016

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

Type

Technology appraisal guidance

Published

27 April 2016

This guideline covers how to improve the health and wellbeing of employees, with a focus on organisational culture and the role of line managers.

Type

NICE guideline

Last updated

24 March 2016

Evidence-based recommendations on ruxolitinib (Jakavi) for treating disease-related splenomegaly or symptoms in adults with myelofibrosis

Type

Technology appraisal guidance

Published

23 March 2016

This guideline covers community engagement approaches to reduce health inequalities, ensure health and wellbeing initiatives are effective and help local authorities and health bodies meet their statutory obligations.

Type

NICE guideline

Published

04 March 2016

Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.

Type

Technology appraisal guidance

Last updated

03 March 2016

Evidence-based recommendations on ezetimibe (Ezetrol) for treating primary heterozygous-familial and non-familial hypercholesterolaemia.

Type

Technology appraisal guidance

Published

24 February 2016

Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults

Type

Technology appraisal guidance

Published

18 February 2016

This guideline covers new buildings and communal outdoor areas. The aim is to ensure there are enough shady areas to protect people from overexposure to the sun.

Type

Public health guideline

Last updated

09 February 2016

This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.

Type

NICE guideline

Published

09 February 2016

Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima…

Type

Technology appraisal guidance

Published

01 February 2016

Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic, hormone-relapsed prostate cancer for people in whom chemotherapy is not yet

Type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on ramucirumab (Cyramza)

Type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on nintedanib (Ofev) for people with idiopathic pulmonary fibrosis.

Type

Technology appraisal guidance

Published

27 January 2016

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Type

Technology appraisal guidance

Published

27 January 2016

NICE is unable to make a recommendation about the use in the NHS of Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive…

Type

Technology appraisal guidance

Published

27 January 2016